Advertisement
Advertisement
U.S. markets open in 1 hour 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2100-0.0068 (-3.14%)
At close: 04:00PM EDT
0.1980 -0.01 (-5.71%)
Pre-Market: 04:13AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close0.2168
Open0.2172
Bid0.1990 x 2900
Ask0.2488 x 1100
Day's Range0.2045 - 0.2172
52 Week Range0.1310 - 2.4000
Volume180,211
Avg. Volume328,106
Market Cap5.876M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-1.3700
Earnings DateMay 15, 2023 - May 19, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BNTC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Benitec Biopharma Inc.
    NKTR: Lowering target price to $0.63NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

    First subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q

  • GlobeNewswire

    Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

    HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) S

  • GlobeNewswire

    Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

    HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.

Advertisement
Advertisement